Active Ingredient(s): Tafamidis Meglumine
FDA Approved: * May 3, 2019
Pharm Company: * FOLDRX PHARMS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vyndaqel Overview

Tafamidis, sold under the brand names Vyndaqel and Vyndamax,[3] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis (ATTR). It can be used to treat both hereditary forms (hATTR), familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP), as well as wild-type transthyretin amyloidosis (wtATTR, formerly called senile systemic amyloidosis). It works by stabilizing the quaternary structure of the protein...

Read more Vyndaqel Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tafamidis

Recent Vyndaqel Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tafamidis Meglumine
  • Capsule: 20mg, 61mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vyndaqel: (2 results)

Sorted by National Drug Code
  • 0069-1975 Vyndaqel 20 mg Oral Capsule, Liquid Filled by Pfizer Laboratories Div Pfizer Inc
  • 0069-8729 Vyndaqel by Pfizer Labs Division of Pfizer Inc.

Other drugs which contain Tafamidis Meglumine or a similar ingredient: (2 results)